Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00142935
Status:
COMPLETED
Last Update Posted:
2014-06-06
First Post:
2005-09-01
Brief Title:
Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
Sponsor:
The Miriam Hospital
Organization:
The Miriam Hospital
Study Overview
Official Title:
Opiate Replacement Therapy at Release From Incarceration
Status:
COMPLETED
Status Verified Date:
2009-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Much of the HIVAIDS epidemic is driven by transmission from or to persons addicted to opiates Many of these individuals pass through a correctional setting each year creating an opportunity for linkage to substance abuse treatment The purpose of this study was to evaluate the effectiveness of initiating opiate replacement therapy prior to release from incarceration on reducing HIV risk behaviors and drug relapse In addition this study evaluated the effectiveness of short-term payment versus non-payment of community opiate replacement therapy immediately following release from incarceration
Detailed Description:
A substantial proportion of individuals addicted to heroin are incarcerated while addicted and a majority of individuals released from a correctional setting have a history of heroin addiction The period immediately after release from incarceration is a particularly high-risk time for HIV transmission and other problems including drug relapse and overdose Methadone treatment is the most widely used opiate replacement therapy in the United States and has been shown to decrease HIV risk as well as drug use addiction relapse and criminal activity The purpose of this study was to evaluate the effectiveness of initiating opiate replacement therapy prior to release from incarceration on reducing HIV risk behaviors and drug relapse In addition this study evaluated the effectiveness of short-term payment versus non-payment of community opiate replacement therapy immediately following release from incarceration
Participants in this were randomly assigned to 1 of 3 treatment groups Participants enrolled in Group 1 initiated methadone opiate replacement therapy about 1 month prior to release from incarceration They proceeded with a methadone program of their choice upon release and received short-term payment to cover treatment costs Participants enrolled in Group 2 were referred to a methadone program of their choice and received short-term payment to cover treatment costs Participants enrolled in Group 3 were referred to a program of choice upon release from incarceration without receiving financial assistance All participants had the opportunity to partake in existing support programs available at the Rhode Island Department of Corrections while incarcerated and in the community upon release Follow-up assessments occurred at Months 15 6 and 12 These included interviews and urine specimens for toxicology analysis to verify self-reports
Participants in this were randomly assigned to 1 of 3 treatment groups Participants enrolled in Group 1 initiated methadone opiate replacement therapy about 1 month prior to release from incarceration They proceeded with a methadone program of their choice upon release and received short-term payment to cover treatment costs Participants enrolled in Group 2 were referred to a methadone program of their choice and received short-term payment to cover treatment costs Participants enrolled in Group 3 were referred to a program of choice upon release from incarceration without receiving financial assistance All participants had the opportunity to partake in existing support programs available at the Rhode Island Department of Corrections while incarcerated and in the community upon release Follow-up assessments occurred at Months 15 6 and 12 These included interviews and urine specimens for toxicology analysis to verify self-reports
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DPMC | None | None | None |
| R01-DA018641-1 | None | None | None |